openPR Logo
Press release

FDA Warns Multaq Users of Potential Health Risks

01-26-2012 07:32 AM CET | Politics, Law & Society

Press release from: Nadrich & Cohen LLP

Nadrich & Cohen, LLP reports that the U.S. Food and Drug Administration has issued an updated safety warning for the heart medication Multaq.

Los Angeles, CA, January 24, 2012 – The U.S. Food and Drug Administration has issued an updated safety communication advising patients who use the heart medication Multaq (dronedarone) of the potential for serious complications.

The updated safety communication was issued on December 19, 2011 after an FDA safety review determined that the drug increased the risk of serious cardiovascular events, including death, when used by patients to treat a heart rhythm condition known as permanent atrial fibrillation (AF).

According to the FDA website, the safety review was based on data drawn from two clinical trials, the PALLAS trial (Permanent Atrial Fibrillation Outcome Study Using Dronedarone on Top of Standard Therapy) and the ATHENA trial, which supported the approval of Multaq for use among patients with non-permanent atrial fibrillation.

The FDA announced that it would require updated warning labels for Multaq advising health care professionals not to give the drug to patients with AF who cannot or will not be converted to permanent AF because it could double the risk heart attack or stroke. The move has many cardiovascular experts closely monitoring the future of the drug.

Multaq was first approved by the FDA in July 2009. Through October 2011, approximately 1.3 million prescriptions were filled for the drug with another 278,000 patients purchasing the drug through outpatient retail pharmacies in the U.S.

Patients who experienced a heart attack, stroke or other complications after taking Multaq are urged to complete a MedWatch form by visiting the Food and Drug Administration’s website. It is also recommended that you contact an experienced persona injury lawyer to discuss your rights.

Nadrich & Cohen LLP offers confidential, no-cost consultations to Multaq users who believe they were harmed by the drug. Help is available by calling the firm’s injury hotline at 1-800-722-0765 or by completing an online case evaluation form at www.personalinjurylawcal.com.

Nadrich & Cohen LLP is a national law firm with offices in Los Angeles, Sacramento, San Diego and other cities throughout California. The firm specializes in handling mass tort actions and representing individuals in cases involving pharmaceutical companies, medical device makers and other product manufacturers. The firm is committed to achieving the best outcome possible in every case and has recovered over $200 million in settlements on behalf of its clients.

In addition to handling Multaq side effects claims, Nadrich & Cohen, LLP investigates cases involving Accutane, Avandia, DePuy Hip Implants, Zimmer Hips, Wright Conserve Hips, Vaginal Mesh, Pradaxa, Stevens-Johnson Syndrome, Reflex Sympathy Dystrophy, Fen Phen and PPH, Depakote and Reglan. All cases are accepted on a contingency basis, meaning there is never a fee unless we recover a judgment on your behalf.

The time you have to file an injury claim is limited, so it’s important to act as quickly as possible to protect your rights. Call 1-800-722-0765 today to speak with a qualified personal injury expert or visit www.personalinjurylawcal.com.

Nadrich & Cohen LLP is a national law firm specializing in representing individuals who have been injured by defective medical devices, harmful prescription drugs, faulty products, car accidents, motorcycle accidents and dog bites. For more information, visit www.personalinjurylawcal.com.

Jennifer Poole
National Client Intake Coordinator
Nadrich & Cohen LLP
12100 Wilshire Blvd.
Suite 1250
Los Angeles, CA 90025
800-718-4658
info@personalinjurylawcal.com
www.personalinjurylawcal.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release FDA Warns Multaq Users of Potential Health Risks here

News-ID: 208309 • Views:

More Releases from Nadrich & Cohen LLP

Yaz Lawsuit Settlements Reach $142 Million
Nadrich & Cohen, LLP reports that Bayer is continuing to offer settlements to plaintiffs involved in federal Yaz side effects litigation. Los Angeles, CA, April 27, 2012 – Nadrich & Cohen, LLP reports that German drug-maker Bayer AG has settled approximately 651 Yaz side effects lawsuits totaling $142 million. Earlier this month, it was reported that the drug-maker had reached settlements in approximately 500 cases filed by women who claimed
Yaz, Yasmin to Get New Labels as FDA Warns of Blood Clot Risk
Nadrich & Cohen, LLP reports that Yaz and similar birth control pills are to receive updated warning labels advising patients of the risk for developing serious blood clots. Los Angeles, CA, April 10, 2012 – National law firm Nadrich & Cohen, LLP has learned that the U.S. Food and Drug Administration has ordered Bayer to produce new warning labels for several of its oral contraceptives, including Yaz, Yasmin and Beyaz.
FDA Schedules Advisory Panel Meeting to Discuss Metal Hip Safety
Nadrich & Cohen, LLP reports that the FDA has scheduled an advisory panel to discuss the safety of metal hip implants. Los Angeles, CA, March 29, 2012 – National law firm Nadrich & Cohen, LLP has learned that the U.S. Food and Drug Administration has a scheduled an advisory panel meeting to discuss the safety of metal hip implants and all-metal hip resurfacing systems. The two-day panel, which is expected
Pradaxa Side Effects Lawsuits Filed in Federal Court
Nadrich & Cohen, LLP reports that three Pradaxa side effects lawsuits have been filed in federal courts across the country. Los Angeles, CA, March 7, 2012 – National law firm Nadrich & Cohen, LLP has learned that three Pradaxa side effects lawsuits have been filed against Boehringer Ingelheim, the drug’s manufacturer. The cases were filed in federal district courts located in Tennessee, Kentucky and Louisiana and it’s believed they are the

All 5 Releases


More Releases for Multaq

Atrial Fibrillation Market to Exceed Value of US$ 18.5 Bn by 2031
Atrial Fibrillation Market Outlook 2031 • The global atrial fibrillation market was valued at US$ 10.2 Bn in 2021 • The global market is projected to grow at a CAGR of 6% from 2022 to 2031 • The global atrial fibrillation market is anticipated to exceed value of US$ 18.5 Bn by 2031 Overview of Global Atrial Fibrillation Market Atrial fibrillation refers to a type of cardiac arrhythmia distinguished by an abnormal cardiac rhythm caused by a disturbance
Atrial Fibrillation Drugs Market 2020 Clinical Area Segmentation - Boehringer In …
Global Atrial Fibrillation Drugs Market Professional Survey Report 2019 Atrial Fibrillation Drugs Market report will make detailed analysis mainly on in-depth research on the development environment, Market size, development trend, operation situation and future development trend of Atrial Fibrillation Drugs Market on the basis of stating current situation of the industry in 2020. This report focuses on Atrial Fibrillation Drugs volume and value at global level, regional level and company level. From
Global Anti-arrhythmic Drugs Market Trends, Regulations And Competitive Landscap …
Cardiovascular diseases is one of the major causes of death across the globe. According to the World Health Organization, the number of deaths caused by these diseases is expected to reach over 23 million by 2030. These are largely lifestyle diseases and about 16% of deaths caused by these diseases in 2012 were attributed to high blood pressure. Various classes of drugs used to treat cardiac disorders include calcium channel
Market Overview: Anti-arrhythmic Drugs Market Size & Share, Growth, Trends, and …
" Anti-arrhythmic Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025" is the latest addition to MarketResearchReports.Biz industry research reports collection. ​The objective of this report is to define, describe, and forecast the market on the basis of type, application, medical condition, and region. It provides detailed information regarding the major factors influencing the growth of the market. This report also tracks and analyzes competitive
Anti-arrhythmic Drugs Market : Segmental Highlights and Table of Content (2017 - …
Cardiovascular diseases is one of the major causes of death across the globe. According to the World Health Organization, the number of deaths caused by these diseases is expected to reach over 23 million by 2030. These are largely lifestyle diseases and about 16% of deaths caused by these diseases in 2012 were attributed to high blood pressure. Various classes of drugs used to treat cardiac disorders include calcium channel